Item 5. Other Information
Item 5. Other Information.
None
47
Item 6. Exhibits.
31.1
Certification of principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
31.2
Certification of principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
32.1
Certification of principal executive officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **
32.2
Certification of principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **
EX-101.INS
XBRL Instance Document *
EX-101.SCH
XBRL Taxonomy Extension Schema Document *
EX-101.CAL
XBRL Taxonomy Extension Calculation Linkbase *
EX-101.DEF
XBRL Taxonomy Extension Definition Linkbase *
EX-101.LAB
XBRL Taxonomy Extension Labels Linkbase *
EX-101.PRE
XBRL Taxonomy Extension Presentation Linkbase *
*
Filed herewith
**
Furnished herewith
48
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Kintara Therapeutics, Inc.
Date: May 13, 2021
By:
/s/ Saiid Zarrabian
Saiid Zarrabian
Chief Executive Officer
(Principal Executive Officer)
Date: May 13, 2021
By:
/s/ Scott Praill
Scott Praill
Chief Financial Officer
(Principal Financial and Accounting Officer)
49
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.